Use of gemcitabine and nab-paclitaxel as a third-line treatment following failure of first line gemcitabine for advanced pancreatic adenocarcinoma

被引：0
|
作者：
McNulty, M. [1 ]
Dean, A. [2 ]
Das, A. [1 ]
Gordon, M. [1 ]
机构：
[1] St John God Hosp Subiaco, Perth, WA, Australia
[2] St John God Hosp Subiaco, Subiaco, WA, Australia
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P - 147
引用
收藏
页数：2
相关论文
共 50 条
  • [41] NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer
    Nichetti, Federico
    Rota, Simone
    Ambrosini, Paolo
    Pircher, Chiara
    Gusmaroli, Eleonora
    Busset, Michele Droz Dit
    Pusceddu, Sara
    Sposito, Carlo
    Coppa, Jorgelina
    Morano, Federica
    Pietrantonio, Filippo
    Di Bartolomeo, Maria
    Mariani, Luigi
    Mazzaferro, Vincenzo
    de Braud, Filippo
    Niger, Monica
    JAMA NETWORK OPEN, 2024, 7 (01)
  • [42] Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric A.
    Aran, Dvir
    JAMA NETWORK OPEN, 2022, 5 (06) : E2216199
  • [43] The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study
    Zhang, Feng
    Wang, Yuyang
    Yang, Fangfang
    Zhang, Yuming
    Jiang, Man
    Zhang, Xiaochun
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 535 - 546
  • [44] Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
    Tempero, M.
    Oh, D-Y
    Tabernero, J.
    Reni, M.
    Van Cutsem, E.
    Hendifar, A.
    Waldschmidt, D-T
    Starling, N.
    Bachet, J-B
    Chang, H-M
    Maurel, J.
    Garcia-Carbonero, R.
    Lonardi, S.
    Coussens, L. M.
    Fong, L.
    Tsao, L. C.
    Cole, G., Jr.
    James, D.
    Macarulla, T.
    ANNALS OF ONCOLOGY, 2021, 32 (05) : 600 - 608
  • [45] Gemcitabine, Cisplatin, and Nab-Paclitaxel as a First-Line Therapy for Advanced Biliary Tract Cancers
    Gedela, Sandeep
    Munot, Pritesh
    Vaidyanathan, Arvind
    Joarder, Ritam
    Chaugule, Deepali
    Parulekar, Manali
    Nashikkar, Chaitali
    Ghadi, Aayushi
    Vadodaria, Divya
    Goel, Mahesh
    Patkar, Shraddha
    Mandavkar, Sarika
    Ramaswamy, Anant
    Bhargava, Prabhat
    Srinivas, Sujay
    Ostwal, Vikas
    JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (01) : 263 - 269
  • [46] Gemcitabine, Cisplatin, and Nab-Paclitaxel as a First-Line Therapy for Advanced Biliary Tract Cancers
    Sandeep Gedela
    Pritesh Munot
    Arvind Vaidyanathan
    Ritam Joarder
    Deepali Chaugule
    Manali Parulekar
    Chaitali Nashikkar
    Aayushi Ghadi
    Divya Vadodaria
    Mahesh Goel
    Shraddha Patkar
    Sarika Mandavkar
    Anant Ramaswamy
    Prabhat Bhargava
    Sujay Srinivas
    Vikas Ostwal
    Journal of Gastrointestinal Cancer, 2024, 55 : 263 - 269
  • [47] Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma
    Bukhari, Nedal
    Abdalla, Khalda
    Ibnshamsa, Fahad
    Alselwi, Waleed
    Al-Shakir, Shakir
    Alqahtani, Mohammed
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (10)
  • [48] Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
    Sezgin, Yasin
    Karhan, Ogur
    Aldemir, Mehmet Naci
    Urun, Muslih
    Ercek, Berrak Mermit
    Urakci, Zuhat
    Arvas, Hayati
    Tunc, Sezai
    Erdem, Mehmet
    Yerlikaya, Halis
    Ileri, Serdar
    Aydin, Ibrahim
    Bicer, Abdurrahman
    Komuroglu, Ahmet Ufuk
    Majidova, Nargiz
    Gokcek, Savas
    Demir, Hacer
    Yildiz, Sedat
    Akbas, Sinem
    Ozen, Esra
    Kahya, Burcu Ulas
    Sali, Muersel
    Anik, Hicran
    Aykut, Talat
    Araz, Murat
    Alkan, Ali
    Ozcelik, Melike
    Sakin, Abudllah
    Aykan, Musa Baris
    Mehtiyev, Mirmehdi
    Demir, Bilgin
    Baser, Mehmet Nuri
    Sonmez, Muge
    Gulturk, Ilkay
    Avci, Niluever
    Urvay, Semiha
    Arici, Mustafa Ozgur
    Kalender, Mehmet Emin
    Yildirim, Mustafa
    Solmaz, Ali Alper
    Gurbuz, Mustafa
    Ergun, Yakup
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [49] A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer
    Fukahori, Masaru
    Miwa, Keisuke
    Murotani, Kenta
    Naito, Yoshiki
    Ushijima, Tomoyuki
    Sakaue, Takahiko
    Tanaka, Toshimitsu
    Nagasu, Sachiko
    Suga, Hideya
    Kakuma, Tatsuyuki
    Okabe, Yoshinobu
    Torimura, Takuji
    MEDICINE, 2021, 100 (20) : E26052
  • [50] Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting
    Braiteh, Fadi
    Patel, Manish B.
    Parisi, Monika
    Ni, Quanhong
    Park, Siyeon
    Faria, Claudio
    CANCER MANAGEMENT AND RESEARCH, 2017, 9 : 141 - 148
12345